Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease - Biogen

Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease    Biogen Biogen advances Alzheimer's drug to late-stage trial despite disappointing data    CNBC Biogen’s tau-targeting Alzheimer’s drug posts mixed results in mid-stage study    statnews.com Biogen advances Alzheimer’s tau program despite midphase miss    Fierce Biotech Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease    Yahoo Finance

Original source: Google News